Ads
related to: sjogren's antibody ssb positive cells treatment for cancer symptoms early
Search results
Results From The WOW.Com Content Network
Immunofluorescence pattern of SS-A and SS-B antibodies. Produced using serum from a patient on HEp-20-10 cells with a FITC conjugate. Anti-SSA autoantibodies (anti–Sjögren's-syndrome-related antigen A autoantibodies, also called anti-Ro, or similar names including anti-SSA/Ro, anti-Ro/SSA, anti–SS-A/Ro, and anti-Ro/SS-A) are a type of anti-nuclear autoantibodies that are associated with ...
20823 Ensembl ENSG00000138385 ENSMUSG00000068882 UniProt P05455 P32067 RefSeq (mRNA) NM_003142 NM_001294145 NM_001110145 NM_009278 NM_001355265 RefSeq (protein) NP_001281074 NP_003133 NP_001103615 NP_033304 NP_001342194 Location (UCSC) Chr 2: 169.79 – 169.81 Mb Chr 2: 69.69 – 69.7 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Sjögren syndrome type B antigen (SS-B) also known ...
Sjögren's disease (SjD) [8] [9] (previously known as Sjögren syndrome or Sjögren's syndrome (SjS, SS)) is a long-term autoimmune disease that primarily affects the body's exocrine glands, particularly the lacrimal and salivary glands.
Anti-cancer monoclonal antibodies can be targeted against malignant cells by several mechanisms. Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment of advanced malignancies. [18] In childhood lymphoma, phase I and II studies have found a positive effect of using antibody therapy. [19]
In addition, tirabrutinib is in clinical development by Ono Pharmaceutical and Gilead Sciences [3] in the United States, Europe, and Japan for autoimmune disorders, chronic lymphocytic leukemia, B cell lymphoma, Sjogren's syndrome, pemphigus, and rheumatoid arthritis. [1] Tirabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase. [4]
This is the highest dilution of the serum at which autoantibodies are still detectable. Positive autoantibody titres at a dilution equal to or greater than 1:160 are usually considered as clinically significant. Positive titres of less than 1:160 are present in up to 20% of the healthy population, especially the elderly.
CD20 is the target of the mAbs rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
The antibodies found in LEMS associated with lung cancer also bind to calcium channels in the cancer cells, and it is presumed that the antibodies originally develop as a reaction to these cells. [4] It has been suggested that the immune reaction to the cancer cells suppresses their growth and improves the prognosis from the cancer. [3] [6]
Ad
related to: sjogren's antibody ssb positive cells treatment for cancer symptoms early